RxDoctor Payments Data

Fahed Saada

Neurology · East Syracuse, NYNPI 1316223613

Payments from drug & device makers

$3,268in general payments, 2019–2025

Across 153 payments — averaging $21.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$597
  • Pfizer$342
  • Genentech USA, Inc.$296
  • Amgen$255
  • AstraZeneca$249
  • Acadia Pharmaceuticals Inc$160
  • plus $1K from 24 others

What the payments were for

  • Food & beverage$3,260100%
  • Education$80%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,268 in reported general payments places this provider in the 60th percentile of 1,623 neurology providers in New York.

See all neurology providers in New York

Medicare billing

Part B allowed, 2024
$75,590
Medicare patients
310
Services billed
1,003

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Nurtec OdtRimegepant Sulfate11$21,314
BriviactBrivaracetam14$18,750
Memantine Hcl210$2,877
Carbidopa-LevodopaCarbidopa/Levodopa72$1,126
Lacosamide18$992
Levetiracetam50$957
Rasagiline Mesylate19$937
Baclofen35$849
Gabapentin82$804
Divalproex Sodium ErDivalproex Sodium15$776
Lamotrigine40$744
Oxcarbazepine11$480
Primidone19$375
Divalproex Sodium29$368
Propranolol Hcl28$362

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerNurtec Odt$342$21,31411 claims
UCB, Inc.Briviact$105$18,75014 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 1,623 neurology providers in New York.

Other neurology in East Syracuse

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →